Global High Potency API CDMOs Market is to rise at a robust double-digit CAGR by 2027

BRUSSELS - Oct. 3, 2023 - PRLog -- High potency active pharmaceutical ingredients (HPAPIs) are a type of pharmaceutical substance that has a strong pharmacological action at low dosages. These are often medications that work in little doses, frequently measured in micrograms (g) or even nanograms (ng).

Biologic HPAPIs and the Evolving Landscape of Drug Development

Targeted treatments are in great demand in the pharmaceutical industry, notably in cancer, where high-potency active pharmaceutical ingredients (HPAPIs) play a vital role. This need has increased the demand for specialist CDMOs with HPAPI development and production capabilities.

For instance,

In March 2022, Lonza and Oasmia announced they had entered into a manufacturing agreement for the production of Oasmia ovarian cancer drug candidate, Cantrixil.

Future Trends in the High Potency API CDMOs Market: Insights from the COVID-19 Experience

The need for high-potency APIs (HPAPIs) increased rapidly during the COVID-19 epidemic. Disruptions in global supply networks and manufacturing caused a halt in research-related initiatives during the early stages of the COVID-19 pandemic. However, in the later half of the pandemic, the business recovered due to the increased demand for coronavirus vaccinations.

In June 2022, WuXi STA, a subsidiary of WuXi AppTec, inaugurated an additional high-potency API (HPAPI) facility at its Changzhou site in Jiangsu, China.

North America holds the largest market share in the global market for high potency API CDMOs.

Because of increased demand for HPAPIs, a favorable regulatory environment, sophisticated healthcare infrastructure, and the presence of numerous major competitors in the area, North America accounts for the biggest market share in the high potency API CDMOs market.

Competitive Landscape Analysis: High Potency API CDMOs Market

Among the established and prominent companies functioning in the global high potency API CDMOs market are Lonza, Sanofi, Pfizer, Novartis AG, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Bayer Healthcare, Merck & Co., Inc., and Wuxi STA.

Organic and Inorganic Growth Strategies Adopted by Key Market Players to Establish Their Foothold in the High Potency API CDMOs Market

In July 2023, Evonik and Heraeus Precious Metals announced about their collaboration to expand their respective service portfolios for highly potent active pharmaceutical ingredients (HPAPIs).

Global high potency API CDMOs market is expected to gain consistent momentum in the coming years as a result of the increasing number of chronic diseases, rising demand for therapeutic and personalized medicines, technological advancements and developments.

Get A Detailed Report on High Potency API CDMOs Market with Competitive Insights @ https://meditechinsights.com/global-high-potency-api-cdmos-market/